Market making agreement
Oslo, Norway, 24 September 2007
A Market Making Agreement has been entered with DnB NOR Markets for the Photocure ASA (PHO) shares listed on Oslo Børs. The agreement is in accordance with the Oslo Børs requirements for the Liquidity Provider scheme. The aim is to achieve a stable spread and liquidity in the shares.
For further information, please contact:
President and CEO Kjetil Hestdal
E-mail: kh@photocure.no
Mobile: +47 913 19 535
CFO Christian Fekete
E-mail: cf@photocure.no
Mobile: +47 916 42 938
www.photocure.com
Photocure ASA is a Norwegian pharmaceutical company listed on the Oslo Stock Exchange. The company develops and sells pharmaceuticals and medical devices for the photodynamic treatment and diagnosis of different types of cancer.
Photocure has three products on the market: Metvix® cream combined with the Aktilite® lamp for the treatment of sun-damaged skin and certain types of skin cancer, and Hexvix® for the diagnosis of bladder cancer. In addition, the company has several follow-on products and technologies in the pipeline.